In the initial phase of the infection, COVID-19 is thought to antagonize type I INF response in the alveolar epithelial cells of the patient’s airways, leading to rapid viral replication and subsequent activation of numerous inflammatory markers, namely IL-6. Here, IL6 is linked to COVID-19.